Cogent Biosciences, Inc.
COGT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $232,658 | $173,755 | $121,627 | $55,913 |
| G&A Expenses | $43,281 | $34,375 | $26,212 | $19,638 |
| SG&A Expenses | $43,281 | $34,375 | $26,212 | $19,638 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $275,939 | $208,130 | $147,839 | $75,551 |
| Operating Income | -$275,939 | -$208,130 | -$147,839 | -$75,551 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $20,080 | $15,720 | $7,598 | $3,278 |
| Pre-Tax Income | -$255,859 | -$192,410 | -$140,241 | -$72,273 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$255,859 | -$192,410 | -$140,241 | -$72,273 |
| % Margin | – | – | – | – |
| EPS | -2.46 | -2.42 | -2.26 | -1.85 |
| % Growth | -1.7% | -7.1% | -22.2% | – |
| EPS Diluted | -2.46 | -2.42 | -2.26 | -1.85 |
| Weighted Avg Shares Out | 103,857 | 79,657 | 58,740 | 38,731 |
| Weighted Avg Shares Out Dil | 103,857 | 79,658 | 58,740 | 38,731 |
| Supplemental Information | – | – | – | – |
| Interest Income | $18,088 | $13,077 | $3,989 | $467 |
| Interest Expense | $0 | $0 | $3,989 | $0 |
| Depreciation & Amortization | $4,351 | $3,588 | $5,878 | $1,991 |
| EBITDA | -$271,588 | -$204,542 | -$141,961 | -$73,560 |
| % Margin | – | – | – | – |